Background
Ivabradine, known for its bradycardic effects, is recommended for HFrEF patients with a sinus rhythm of ≥70 bpm who are on maximum beta blocker doses or when beta blockers are contraindicated. This study aimed to evaluate the clinical and haemodynamic outcomes of Ivabradine in HFrEF patients.
Methods
A systematic review and meta-analysis were conducted, sourcing data from ClinicalTrials.gov, OpenMD, ProQuest, PubMed, and ScienceDirect. The study utilized the random effect model for pooled effects analysis.
Results
The analysis included 18,972 HF patients from nine RCTs. Ivabradine was found to decrease the risk of HF mortality (RR 0.79; 95% CI 0.64–0.98; p=0.03) and HF hospitalization (RR 0.80; 95% CI 0.65–0.97; p=0.03). It also significantly reduced heart rate (MD -12.21; 95% CI -15.47 – -8.96; p<0.01) and improved left ventricular ejection fraction (LVEF) (MD 3.24; 95% CI 2.17–4.31; p <0.01) compared to placebo. However, the risk of asymptomatic (RR 4.25; 95% CI 3.36–5.39; p<0.01) and symptomatic bradycardia (RR 3.99; 95% CI 3.17–5.03; p<0.01) was higher in the Ivabradine group.
Conclusion
Ivabradine offers clinical and haemodynamic benefits for HFrEF patients, including reduced risks of HF mortality and hospitalization, and improvements in resting heart rate and LVEF. Nonetheless, its use is associated with a higher risk of bradycardia, both symptomatic and asymptomatic.
Introduction
Resting heart rate is a critical predictive factor in HFrEF, with higher rates indicating increased sympathetic activity and disease progression. Current guidelines recommend achieving a resting heart rate <70 bpm for HFrEF patients. Beta blockers, despite being a cornerstone in HFrEF management, often fail to achieve this target in clinical practice. Ivabradine, by inhibiting the "funny channel (If)" in the sinoatrial node, offers a novel approach to heart rate reduction without affecting cardiac contractility or airway smooth muscle contraction.
Discussion
The study highlights Ivabradine's efficacy in reducing HF mortality and hospitalization risks, alongside its ability to lower resting heart rate and improve LVEF. However, the increased risk of bradycardia necessitates careful patient selection and monitoring. The findings underscore the importance of Ivabradine as a complementary treatment in HFrEF management, particularly for patients who cannot achieve optimal heart rate control with beta blockers alone.
